Symptoms, SARS-CoV-2 Antibodies, and Neutralization Capacity in a Cross Sectional-Population of German Children

被引:8
|
作者
Laub, Otto [1 ]
Leipold, Georg [2 ]
Toncheva, Antoaneta A. [3 ]
Peterhoff, David [4 ,5 ]
Einhauser, Sebastian [4 ]
Neckermann, Patrick [4 ]
Borchers, Natascha [3 ]
Santos-Valente, Elisangela [3 ]
Kheiroddin, Parastoo [3 ]
Buntrock-Doepke, Heike [3 ,6 ]
Laub, Sarah [1 ]
Schoeberl, Patricia [3 ,6 ]
Schweiger-Kabesch, Andrea [3 ]
Ewald, Dominik [7 ]
Horn, Michael [8 ]
Niggel, Jakob [9 ]
Ambrosch, Andreas [10 ]
Ueberla, Klaus [11 ,12 ]
Gerling, Stephan [3 ]
Brandstetter, Susanne [3 ,6 ]
Wagner, Ralf [4 ,5 ]
Kabesch, Michael [3 ,6 ]
机构
[1] Pediat Off Laub, Rosenheim, Germany
[2] Pediat Off Dr Leipold, Regensburg, Germany
[3] Univ Regensburg, Hosp St Hedwig Order St John, Univ Childrens Hosp Regensburg KUNO, Regensburg, Germany
[4] Univ Regensburg, Inst Med Microbiol & Hyg, Mol Microbiol Virol, Regensburg, Germany
[5] Univ Hosp, Inst Clin Microbiol & Hyg, Regensburg, Germany
[6] Hosp St Hedwig Order St John, Res & Dev Campus Regensburg WECARE, Regensburg, Germany
[7] Pediat Off Dr Heuschmann & Dr Ewald, Regenstauf, Germany
[8] Pediat Off Dr Horn, Schonau, Germany
[9] Maganamed Ltd, Regensburg, Germany
[10] Hosp Order St John, Inst Lab Med Microbiol & Hyg, Regensburg, Germany
[11] FAU Erlangen Nuremberg, Inst Clin & Mol Virol, Erlangen, Germany
[12] Univ Klinikum Erlangen, Erlangen, Germany
来源
FRONTIERS IN PEDIATRICS | 2021年 / 9卷
关键词
antibody; neutralizing; COVID-19; SARS-CoV-2; children;
D O I
10.3389/fped.2021.678937
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background: Children and youth are affected rather mildly in the acute phase of COVID-19 and thus, SARS-CoV-2 infection infection may easily be overlooked. In the light of current discussions on the vaccinations of children it seems necessary to better identify children who are immune against SARS-CoV-2 due to a previous infection and to better understand COVID-19 related immune reactions in children. Methods: In a cross-sectional design, children aged 1-17 were recruited through primary care pediatricians for the study (a) randomly, if they had an appointment for a regular health check-up or (b) if parents and children volunteered and actively wanted to participate in the study. Symptoms were recorded and two antibody tests were performed in parallel directed against S (in house test) and N (Roche Elecsys) viral proteins. In children with antibody response in either test, neutralization activity was determined. Results: We identified antibodies against SARS-CoV-2 in 162 of 2,832 eligible children (5.7%) between end of May and end of July 2020 in three, in part strongly affected regions of Bavaria in the first wave of the pandemic. Approximately 60% of antibody positive children (n = 97) showed high levels (>97th percentile) of antibodies against N-protein, and for the S-protein, similar results were found. Sufficient neutralizing activity was detected for only 135 antibody positive children (86%), irrespective of age and sex. Initial COVID-19 symptoms were unspecific in children except for the loss of smell and taste and unrelated to antibody responses or neutralization capacity. Approximately 30% of PCR positive children did not show seroconversion in our small subsample in which PCR tests were performed. Conclusions: Symptoms of SARS-CoV-2 infections are unspecific in children and antibody responses show a dichotomous structure with strong responses in many and no detectable antibodies in PCR positive children and missing neutralization activity in a relevant proportion of the young population.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies
    Rouet, Romain
    Mazigi, Ohan
    Walker, Gregory J.
    Langley, David B.
    Sobti, Meghna
    Schofield, Peter
    Lenthall, Helen
    Jackson, Jennifer
    Ubiparipovic, Stephanie
    Henry, Jake Y.
    Abayasingam, Arunasingam
    Burnett, Deborah
    Kelleher, Anthony
    Brink, Robert
    Bull, Rowena A.
    Turville, Stuart
    Stewart, Alastair G.
    Goodnow, Christopher C.
    Rawlinson, William D.
    Christ, Daniel
    MABS, 2021, 13 (01)
  • [22] SARS-CoV-2 seroprevalence among children in Latvia: A cross-sectional study
    Sapronova, Krista
    Kake, Ruta
    Pavare, Jana
    Gravele, Dagne
    Sela, Ivita
    Ergle, Estere
    Isarova, Dana
    Grinberga, Zanda
    Zavadska, Dace
    MEDICINE, 2023, 102 (06)
  • [23] The role of single-domain antibodies (or nanobodies) in SARS-CoV-2 neutralization
    Zebardast, Arghavan
    Hosseini, Parastoo
    Hasanzadeh, Ali
    Latifi, Tayebeh
    MOLECULAR BIOLOGY REPORTS, 2022, 49 (01) : 647 - 656
  • [24] The role of single-domain antibodies (or nanobodies) in SARS-CoV-2 neutralization
    Arghavan Zebardast
    Parastoo Hosseini
    Ali Hasanzadeh
    Tayebeh latifi
    Molecular Biology Reports, 2022, 49 : 647 - 656
  • [25] Prevalence of SARS-CoV-2 antibodies in the Palestinian population: A primary health center-based cross-sectional study
    Maraqa, Beesan
    Basha, Walid
    Khayyat, Rasha
    Abdul-Hadi, Abdul-Rahman
    Jabareen, Jurouh
    Al-Shakhra, Kamal
    Al-Kaila, Mai
    Nazzal, Zaher
    PLOS ONE, 2021, 16 (10):
  • [26] Prediction models for neutralization activity against emerging SARS-CoV-2 variants: A cross-sectional study
    Goto, Atsushi
    Miyakawa, Kei
    Nakayama, Izumi
    Yagome, Susumu
    Xu, Juan
    Kaneko, Makoto
    Ohtake, Norihisa
    Kato, Hideaki
    Ryo, Akihide
    FRONTIERS IN MICROBIOLOGY, 2023, 14
  • [27] Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike
    Changrob, Siriruk
    Fu, Yanbin
    Guthmiller, Jenna J.
    Halfmann, Peter J.
    Li, Lei
    Stamper, Christopher T.
    Dugan, Haley L.
    Accola, Molly
    Rehrauer, William
    Zheng, Nai-Ying
    Huang, Min
    Wang, Jiaolong
    Erickson, Steven A.
    Utset, Henry A.
    Graves, Hortencia M.
    Amanat, Fatima
    Sather, D. Noah
    Krammer, Florian
    Kawaoka, Yoshihiro
    Wilson, Patrick C.
    MBIO, 2021, 12 (06):
  • [28] Evaluation of a surrogate virus neutralization assay for detecting neutralizing antibodies against SARS-CoV-2 in an African population
    Nkinda, Lilian
    Shayo, Victoria
    Masoud, Salim
    Barabona, Godfrey
    Ngare, Isaac
    Kunambi, Ponsian P.
    Nkuwi, Emmanuel
    Kamori, Doreen
    Msafiri, Frank
    Osati, Elisha
    Hassan, Frank Eric
    Kisuse, Juma
    Kidenya, Benson
    Mfinanga, Sayoki
    Senkoro, Mbazi
    Ueno, Takamasa
    Lyamuya, Eligius
    Balandya, Emmanuel
    BIOLOGY METHODS & PROTOCOLS, 2025, 10 (01):
  • [29] Structural basis of broad SARS-CoV-2 cross-neutralization by affinity-matured public antibodies
    Sheward, Daniel J.
    Pushparaj, Pradeepa
    Das, Hrishikesh
    Greaney, Allison J.
    Kim, Changil
    Kim, Sungyong
    Hanke, Leo
    Hyllner, Erik
    Dyrdak, Robert
    Lee, Jimin
    Dopico, Xaquin Castro
    Dosenovic, Pia
    Peacock, Thomas P.
    McInerney, Gerald M.
    Albert, Jan
    Corcoran, Martin
    Bloom, Jesse D.
    Murrell, Ben
    Hedestam, Gunilla B. Karlsson
    Hallberg, B. Martin
    CELL REPORTS MEDICINE, 2024, 5 (06)
  • [30] CSF Cytokines and SARS-CoV-2 Antibodies in Children with Neuropsychiatric Symptoms and COVID-19
    Gombolay, G.
    Ngo, B.
    Lapp, S.
    Siegel, B.
    Patel, V
    Hussaini, L.
    Bora, S.
    Philbrook, B.
    Weinschenk, K.
    Wright, L.
    Anderson, E.
    Rostad, C.
    ANNALS OF NEUROLOGY, 2021, 90 : S109 - S110